Additionally, drugs predicted to target the NFE2L2 gene, such as Lagascatriol, Andalusol, Irofulven, NK-252, RTA-408, and Sulforaphane, are commonly employed to alleviate RA inflammation in clinical practice. Here, NFE2L2 is linked to rheumatoid arthritis.